The present invention administers to a subject a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 for the treatment of cancer and / or inflammation. It is intended for combination therapy. The present invention also includes a first molecule that specifically binds human B7-H3 that can mediate, more preferably enhance, the activation of the immune system against cancer cells associated with any of a variety of human cancers. And a pharmaceutical composition comprising a second molecule that specifically binds to human PD-1. The present invention also relates to the use of a pharmaceutical composition as described above for treating cancer and other diseases in a recipient subject.本発明は、癌及び／又は炎症の治療のために、ヒトＢ７‐Ｈ３に特異的に結合する第１の分子と、ヒトＰＤ‐１に特異的に結合する第２の分子とを被験者に投与することを伴う、併用療法を対象とする。本発明はまた、多様なヒトの癌のうちのいずれに関連する癌細胞に対する免疫系の活性化を仲介でき、より好ましくは増強できる、ヒトＢ７‐Ｈ３に特異的に結合する第１の分子と、ヒトＰＤ‐１に特異的に結合する第２の分子とを含む医薬組成物にも関する。本発明はまた、レシピエント被験者の癌及び他の疾患を治療するための、上述のような医薬組成物の使用にも関する。
